NCT02135133 2026-03-17A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLDana-Farber Cancer InstitutePhase 2 Completed27 enrolled 7 charts
NCT02787369 2026-01-07ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLDana-Farber Cancer InstitutePhase 1 Active not recruiting3 enrolled